Application of bulleyaconitine A in preparing medicament for treating primary erythermalgia

Abstract

The invention relates to an application of bulleyaconitine A to preparing a medicament treating primary erythromelalgia, and belongs to a medicament containing effective organic components, especially to a medicament using bulleyaconitine A to treat diseases. The medicament comprises excipient having filling, binding, disintegrating and lubricating functions, which is mixed with the bulleyaconitine A and then pressed into tablets. Each bulleyaconitine A tablet contains 0.1-0.7mg of bulleyaconitine A or 0.2-0.4mg of bulleyaconitine A. Experiments show the bulleyaconitine A is necessary to treat primary erythromelalgia. Pharmacological mechanisms show that bulleyaconitine A increases sodium current of wild NaV1.7 cell strains by means of concentration dependence so as to cause an activatingcurve to move to hyperpolarizing direction and inhibiting effect thereof on activated Na<+> current can reach 90%.

Description

technical field [0001] The invention belongs to medicines containing effective organic ingredients, in particular to medicines for treating diseases with orthoquinone. Background technique [0002] Primary erythromatalgia is a disease of the autonomic nervous system characterized by paroxysmal vasodilation of distal extremities, elevated skin temperature, flushing of the complexion, and severe burning pain. The etiology of the disease is unknown, and it is usually judged that it may be related Cold-induced dysfunction of capillary dilation in the extremities. Due to the expansion of small arteries in the extremities, the blood flow increases significantly, local congestion, increased intravascular tension, compression or stimulation of arteries and adjacent nerve endings cause severe pain, and the disease is easily induced in environments such as sudden drop in temperature and cold or long-distance marching. Rest, elevate the affected limb, and local cold compresses can be ...

AI Technical Summary

Problems solved by technology

But for the active state Na + Current, the more accurate inhibitory mechanism and effect of aconitin have not yet been proved experimentally, and there is no report on the use of aconitin to relieve primary erythematous limb pain

Images